Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Mifepristone (RU-482)

Last Updated: 02/16/18


Chemical Structure, Mifepristone, RU-482

Index

  1. Status
  2. Tumor Target
  3. Class
  4. Class

Status: Phase 0 - NF2 Pre-Clinical

Tumor Target: Vestibular Schwannoma (VS)

Class: Progesterone Receptor Antagonist

Massachusetts Eye and Ear researchers have shown that Mifepristone (RU-482), a drug currently FDA-approved for chemical abortion, can also prevent the growth of vestibular schwannoma.

"Adverse effects for mifepristone include mild fatigue, hot flashes, nausea and rash. Long-term use of mifepristone has been studied in clinical trials for other tumors, with minimal adverse effects reported after years of usage.[1]

"Side Effects; nausea, vomiting, diarrhea, weakness, or dizziness may occur. Serious side effects; fever of 100.4 degrees F (38 degrees C) or higher, fainting, fast heartbeat, stomach/abdominal pain or tenderness."[5]

Sources

  1. Massachusetts Eye and Ear. "Mifepristone may halt growth of intracranial tumor that causes hearing loss." (2018)
    Source: https://www.masseyeandear.org/news/press-releases/2018/04/mifepristone-may-halt-growth-of-intracranial-tumor-that-causes- hearing-loss
  2. Nature. "Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma."(2018)
    Source: https://www.nature.com/articles/s41598-018-23609-7
  3. FDA. "Mifeprex (mifepristone) Information" (2018)
    Source: https://www.fda.gov/Drugs/DrugSafety/ucm111323.htm
  4. ScienceDaily. "Mifepristone may halt growth of intracranial tumor that causes hearing loss." (2018)
    Source: https://www.sciencedaily.com/releases/2018/04/180403115950.htm
  5. WebMD. "Mifepristone Tablet" (2018)
    Source: https://www.webmd.com/drugs/2/drug-20222-325/mifepristone-oral/mifepristone-oral/details
  6. ChemSpider. "Mifepristone."
    Source: http://www.chemspider.com/Chemical-Structure.49889.html